普萘洛尔治疗婴幼儿血管瘤的临床疗效研究

Clinical study of propranolol in the treatment of infantile hemangioma

目的探讨普萘洛尔治疗婴幼儿血管瘤的临床疗效。方法56例婴幼儿血管瘤患儿,使用数字分组的方式分为对照组及研究组,各28例。对照组接受常规治疗,研究组接受普萘洛尔治疗。对比两组患儿的治疗效果,不良反应发生情况及治疗前后血管内皮生长因子(VEGF)、表皮生长因子样结构域蛋白7(EGFL7)、缺氧诱导因子-1α(HIF-1α)、基质金属蛋白酶-9(MMP-9)水平。结果治疗后,研究组VEGF(126.72±23.94)pg/ml、EGFL7(7.47±2.81)pg/ml、HIF-1α(15.72±2.92)mg/ml、MMP-9(745.74±54.81)pg/ml低于对照组的(184.74±35.25)pg/ml、(13.74±5.82)pg/ml、(20.74±2.85)mg/ml、(824.75±42.33)pg/ml,差异有统计学意义(P<0.05)。研究组治疗总有效率100.00%高于对照组的82.14%,差异有统计学意义(P<0.05)。研究组不良反应发生率7.14%显著低于对照组的39.29%,差异有统计学意义(P<0.05)。结论婴幼儿血管瘤采用普萘洛尔治疗的临床效果显著,可使VEGF、EGFL7、HIF-1α、MMP-9水平得到改善,从而促进血管瘤消退,保证了患儿的健康安全,该治疗方法值得推广。

Objective To discuss the clinical efficacy of propranolol in the treatment of infantile hemangioma.Methods A total of 56 cases of infantile hemangioma were divided into control group and research group according to number grouping method,with 28 cases in each group.The control group was treated with conventional therapy,and the research group was treated with propranolol.The therapeutic effect,occurrence of adverse reactions,vascular endothelial growth factor(VEGF),epidermal growth factor-like domain 7(EGFL7),hypoxia-inducible factor-1α(HIF-1α)and matrix metalloproteinase-9(MMP-9)before and after treatment were compared between the two groups.Results After treatment,the VEGF(126.72±23.94)pg/ml,EGFL7(7.47±2.81)pg/ml,HIF-1α(15.72±2.92)mg/ml,MMP-9(745.74±54.81)pg/ml of the research group were lower than(184.74±35.25)pg/ml,(13.74±5.82)pg/ml,(20.74±2.85)mg/ml,(824.75±42.33)pg/ml of the control group,and the difference was statistically significant(P<0.05).The total effective rate 100.00%of the research group was higher than 82.41%of the control group,and the difference was statistically significant(P<0.05).The incidence of adverser reactions 7.14%of the research group was significantly lower than 39.29%of the control group,and the difference was statistically significant(P<0.05).Conclusion Propranolol has remarkable clinical effect on infantile hemangioma,which can improve the levels of VEGF,EGFL7,HIF-1α,MMP-9,so as to promote the regression of hemangioma and ensure the health and safety of children.This treatment method is worthy of promotion.